Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Emergent BioSolutions Inc (NYSE:EBS)

46.80
Delayed Data
As of Dec 15
 +0.51 / +1.10%
Today’s Change
27.94
Today|||52-Week Range
47.37
+42.51%
Year-to-Date
Lilly Issues Guidance for 2018, New Drugs to Drive Top Line
Dec 14 / Zacks.com - Paid Partner Content
BioMarin Pharmaceutical (BMRN) Jumps: Stock Rises 7.5%
Dec 12 / Zacks.com - Paid Partner Content
Five Marvelous Momentum Stocks to Buy Now
Dec 12 / Zacks.com - Paid Partner Content
Vertex Kalydeco Study Successful in Children Aged 1-2 Years
Dec 08 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close46.29
Today’s open46.71
Day’s range46.33 - 46.95
Volume764,575
Average volume (3 months)369,292
Market cap$1.9B
Data as of 4:06pm ET, 12/15/2017

Growth & Valuation

Earnings growth (last year)-19.86%
Earnings growth (this year)+21.33%
Earnings growth (next 5 years)+22.00%
Revenue growth (last year)-6.50%
P/E ratio27.5
Price/Sales3.31
Price/Book3.18

Competitors

 Today’s
change
Today’s
% change
PCRXPacira Pharmaceutica...-0.85-1.90%
LXRXLexicon Pharmaceutic...+0.06+0.59%
INVAInnoviva Inc+0.15+1.13%
MYOKMyoKardia Inc-0.55-1.42%
Data as of 4:00pm ET, 12/15/2017

Financials

Next reporting dateMarch 8, 2018
EPS forecast (this quarter)$0.58
Annual revenue (last year)$488.8M
Annual profit (last year)$51.8M
Net profit margin12.79%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Daniel J. Abdun-Nabi
Executive VP-
Business Operations
Adam R. Havey
Corporate headquarters
Gaithersburg, Maryland

Forecasts